"use strict";(self.webpackChunkbuild_back_better_breakdown=self.webpackChunkbuild_back_better_breakdown||[]).push([[7584],{3905:function(e,n,t){t.d(n,{Zo:function(){return p},kt:function(){return h}});var a=t(7294);function i(e,n,t){return n in e?Object.defineProperty(e,n,{value:t,enumerable:!0,configurable:!0,writable:!0}):e[n]=t,e}function r(e,n){var t=Object.keys(e);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);n&&(a=a.filter((function(n){return Object.getOwnPropertyDescriptor(e,n).enumerable}))),t.push.apply(t,a)}return t}function o(e){for(var n=1;n<arguments.length;n++){var t=null!=arguments[n]?arguments[n]:{};n%2?r(Object(t),!0).forEach((function(n){i(e,n,t[n])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(t)):r(Object(t)).forEach((function(n){Object.defineProperty(e,n,Object.getOwnPropertyDescriptor(t,n))}))}return e}function s(e,n){if(null==e)return{};var t,a,i=function(e,n){if(null==e)return{};var t,a,i={},r=Object.keys(e);for(a=0;a<r.length;a++)t=r[a],n.indexOf(t)>=0||(i[t]=e[t]);return i}(e,n);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);for(a=0;a<r.length;a++)t=r[a],n.indexOf(t)>=0||Object.prototype.propertyIsEnumerable.call(e,t)&&(i[t]=e[t])}return i}var c=a.createContext({}),d=function(e){var n=a.useContext(c),t=n;return e&&(t="function"==typeof e?e(n):o(o({},n),e)),t},p=function(e){var n=d(e.components);return a.createElement(c.Provider,{value:n},e.children)},u={inlineCode:"code",wrapper:function(e){var n=e.children;return a.createElement(a.Fragment,{},n)}},l=a.forwardRef((function(e,n){var t=e.components,i=e.mdxType,r=e.originalType,c=e.parentName,p=s(e,["components","mdxType","originalType","parentName"]),l=d(t),h=i,f=l["".concat(c,".").concat(h)]||l[h]||u[h]||r;return t?a.createElement(f,o(o({ref:n},p),{},{components:t})):a.createElement(f,o({ref:n},p))}));function h(e,n){var t=arguments,i=n&&n.mdxType;if("string"==typeof e||i){var r=t.length,o=new Array(r);o[0]=l;var s={};for(var c in n)hasOwnProperty.call(n,c)&&(s[c]=n[c]);s.originalType=e,s.mdxType="string"==typeof e?e:i,o[1]=s;for(var d=2;d<r;d++)o[d]=t[d];return a.createElement.apply(null,o)}return a.createElement.apply(null,t)}l.displayName="MDXCreateElement"},3004:function(e,n,t){t.r(n),t.d(n,{frontMatter:function(){return s},contentTitle:function(){return c},metadata:function(){return d},toc:function(){return p},default:function(){return l}});var a=t(7462),i=t(3366),r=(t(7294),t(3905)),o=["components"],s={sidebar_position:3},c="Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries",d={unversionedId:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3",id:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3",title:"Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries",description:"SEC. 139201. MEDICARE PART D BENEFIT REDESIGN.",source:"@site/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3.md",sourceDirName:"title-13-committee-on-ways-and-means/title-13-subtitle-j",slug:"/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3",editUrl:"https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3.md",tags:[],version:"current",sidebarPosition:3,frontMatter:{sidebar_position:3},sidebar:"tutorialSidebar",previous:{title:"Part 2 - Prescription Drug Inflation Rebates",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2"},next:{title:"Part 4 - Repeal Of Certain Prescription Drug Rebate Rule",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-4"}},p=[{value:"SEC. 139201. MEDICARE PART D BENEFIT REDESIGN.",id:"sec-139201-medicare-part-d-benefit-redesign",children:[],level:2}],u={toc:p};function l(e){var n=e.components,t=(0,i.Z)(e,o);return(0,r.kt)("wrapper",(0,a.Z)({},u,t,{components:n,mdxType:"MDXLayout"}),(0,r.kt)("h1",{id:"part-3---part-d-improvements-and-maximum-out-of-pocket-cap-for-medicare-beneficiaries"},"Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries"),(0,r.kt)("h2",{id:"sec-139201-medicare-part-d-benefit-redesign"},"SEC. 139201. MEDICARE PART D BENEFIT REDESIGN."),(0,r.kt)("pre",null,(0,r.kt)("code",{parentName:"pre"},"(a) Benefit Structure Redesign.--Section 1860D-2(b) of the Social \n")),(0,r.kt)("p",null,"Security Act (42 U.S.C. 1395w-102(b)) is amended--\n(1) in paragraph (2)--\n(A) in subparagraph (A), in the matter preceding\nclause (i), by inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024 \n                and for costs above the annual deductible specified in \n                paragraph (1) and up to the annual out-of-pocket \n                threshold specified in paragraph (4)(B) for 2024 and \n                each subsequent year'' after "),"paragraph (3)'';\n(B) in subparagraph (C)--\n(i) in clause (i), in the matter preceding\nsubclause (I), by inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a year \n                        preceding 2024,'' after "),"paragraph (4),''; and\n(ii) in clause (ii)(III), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"and \n                        each subsequent year'' and inserting "),"through\n2023''; and\n(C) in subparagraph (D)--\n(i) in clause (i)--\n(I) in the matter preceding\nsubclause (I), by inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a \n                                year preceding 2024,'' after \n                                "),"paragraph (4),''; and\n(II) in subclause (I)(bb), by\nstriking ",(0,r.kt)("inlineCode",{parentName:"p"},"a year after 2018'' and \n                                inserting "),"each of years 2018 through\n2023''; and\n(ii) in clause (ii)(V), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"2019 \n                        and each subsequent year'' and inserting "),"each\nof years 2019 through 2023'';\n(2) in paragraph (3)(A)--\n(A) in the matter preceding clause (i), by\ninserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024,'' after "),"and\n(4),''; and\n(B) in clause (ii), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"for a subsequent \n                year'' and inserting "),"for each of years 2007 through\n2023''; and\n(3) in paragraph (4)--\n(A) in subparagraph (A)--\n(i) in clause (i)--\n(I) by redesignating subclauses (I)\nand (II) as items (aa) and (bb),\nrespectively, and moving the margin of\neach such redesignated item 2 ems to\nthe right;\n(II) in the matter preceding item\n(aa), as redesignated by subclause (I),\nby striking ",(0,r.kt)("inlineCode",{parentName:"p"},"is equal to the greater \n                                of--'' and inserting "),"is equal to--\n",(0,r.kt)("inlineCode",{parentName:"p"},"(I) for a year preceding 2024, \n                                the greater of--'';\n                                    (III) by striking the period at the \n                                end of item (bb), as redesignated by \n                                subclause (I), and inserting "),"; and'';\nand\n(IV) by adding at the end the\nfollowing:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(II) for 2024 and each succeeding \n                                year, $0.''; and\n                            (ii) in clause (ii), by striking "),"clause\n(i)(I)'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"clause (i)(I)(aa)'';\n                    (B) in subparagraph (B)--\n                            (i) in clause (i)--\n                                    (I) in subclause (V), by striking \n                                "),"or'' at the end;\n(II) in subclause (VI)--\n(aa) by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"for a \n                                        subsequent year'' and inserting \n                                        "),"for each of years 2021\nthrough 2023''; and\n(bb) by striking the period\nat the end and inserting a\nsemicolon; and\n(III) by adding at the end the\nfollowing new subclauses:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(VII) for 2024, is equal to \n                                $2,000; or\n                                    "),"(VIII) for a subsequent year, is\nequal to the amount specified in this\nsubparagraph for the previous year,\nincreased by the annual percentage\nincrease described in paragraph (6) for\nthe year involved.''; and\n(ii) in clause (ii), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"clause \n                        (i)(II)'' and inserting "),"clause (i)'';\n(C) in subparagraph (C)(i), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"and for \n                amounts'' and inserting "),"and, for a year preceding\n2024, for amounts''; and\n(D) in subparagraph (E), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"In \n                applying'' and inserting "),"For each of years 2011\nthrough 2023, in applying''.\n(b) Decreasing Reinsurance Payment Amount.--Section 1860D-15(b)(1)\nof the Social Security Act (42 U.S.C. 1395w-115(b)(1)) is amended by\ninserting after ",(0,r.kt)("inlineCode",{parentName:"p"},"80 percent'' the following: "),"(or, with respect to a\ncoverage year after 2023, 20 percent)''.\n(c) Manufacturer Discount Program.--\n(1) In general.--Part D of title XVIII of the Social\nSecurity Act (42 U.S.C. 1395w-101 et seq.), as amended by\nsection 139102, is further amended by inserting after section\n1860D-14B the following new section:"),(0,r.kt)("p",null,"``SEC. 1860D-14C. MANUFACTURER DISCOUNT PROGRAM."),(0,r.kt)("pre",null,(0,r.kt)("code",{parentName:"pre"},"``(a) Establishment.--The Secretary shall establish a manufacturer \n")),(0,r.kt)("p",null,"discount program (in this section referred to as the ",(0,r.kt)("inlineCode",{parentName:"p"},"program'). Under \nthe program, the Secretary shall enter into agreements described in \nsubsection (b) with manufacturers and provide for the performance of \nthe duties described in subsection (c). The Secretary shall establish a \nmodel agreement for use under the program by not later than January 1, \n2023, in consultation with manufacturers, and allow for comment on such \nmodel agreement.\n    ``(b) Terms of Agreement.--\n            ``(1) In general.--\n                    ``(A) Agreement.--An agreement under this section \n                shall require the manufacturer to provide applicable \n                beneficiaries access to discounted prices for \n                applicable drugs of the manufacturer that are dispensed \n                on or after January 1, 2024.\n                    ``(B) Provision of discounted prices at the point-\n                of-sale.--The discounted prices described in \n                subparagraph (A) shall be provided to the applicable \n                beneficiary at the pharmacy or by the mail order \n                service at the point-of-sale of an applicable drug.\n                    ``(C) Timing of agreement.--\n                            ``(i) Special rule for 2024.--In order for \n                        an agreement with a manufacturer to be in \n                        effect under this section with respect to the \n                        period beginning on January 1, 2024, and ending \n                        on December 31, 2024, the manufacturer shall \n                        enter into such agreement not later than 30 \n                        days after the date of the establishment of a \n                        model agreement under subsection (a).\n                            ``(ii) 2025 and subsequent years.--In order \n                        for an agreement with a manufacturer to be in \n                        effect under this section with respect to plan \n                        year 2025 or a subsequent plan year, the \n                        manufacturer shall enter into such agreement \n                        (or such agreement shall be renewed under \n                        paragraph (4)(A)) not later than January 30 of \n                        the preceding year.\n            ``(2) Provision of appropriate data.--Each manufacturer \n        with an agreement in effect under this section shall collect \n        and have available appropriate data, as determined by the \n        Secretary, to ensure that it can demonstrate to the Secretary \n        compliance with the requirements under the program.\n            ``(3) Compliance with requirements for administration of \n        program.--Each manufacturer with an agreement in effect under \n        this section shall comply with requirements imposed by the \n        Secretary or a third party with a contract under subsection \n        (d)(3), as applicable, for purposes of administering the \n        program, including any determination under subparagraph (A) of \n        subsection (c)(1) or procedures established under such \n        subsection (c)(1).\n            ``(4) Length of agreement.--\n                    ``(A) In general.--An agreement under this section \n                shall be effective for an initial period of not less \n                than 12 months and shall be automatically renewed for a \n                period of not less than 1 year unless terminated under \n                subparagraph (B).\n                    ``(B) Termination.--\n                            ``(i) By the secretary.--The Secretary may \n                        provide for termination of an agreement under \n                        this section for a knowing and willful \n                        violation of the requirements of the agreement \n                        or other good cause shown. Such termination \n                        shall not be effective earlier than 30 days \n                        after the date of notice to the manufacturer of \n                        such termination. The Secretary shall provide, \n                        upon request, a manufacturer with a hearing \n                        concerning such a termination, and such hearing \n                        shall take place prior to the effective date of \n                        the termination with sufficient time for such \n                        effective date to be repealed if the Secretary \n                        determines appropriate.\n                            ``(ii) By a manufacturer.--A manufacturer \n                        may terminate an agreement under this section \n                        for any reason. Any such termination shall be \n                        effective, with respect to a plan year--\n                                    ``(I) if the termination occurs \n                                before January 30 of a plan year, as of \n                                the day after the end of the plan year; \n                                and\n                                    ``(II) if the termination occurs on \n                                or after January 30 of a plan year, as \n                                of the day after the end of the \n                                succeeding plan year.\n                            ``(iii) Effectiveness of termination.--Any \n                        termination under this subparagraph shall not \n                        affect discounts for applicable drugs of the \n                        manufacturer that are due under the agreement \n                        before the effective date of its termination.\n                            ``(iv) Notice to third party.--The \n                        Secretary shall provide notice of such \n                        termination to a third party with a contract \n                        under subsection (d)(3) within not less than 30 \n                        days before the effective date of such \n                        termination.\n    ``(c) Duties Described.--The duties described in this subsection \nare the following:\n            ``(1) Administration of program.--Administering the \n        program, including--\n                    ``(A) the determination of the amount of the \n                discounted price of an applicable drug of a \n                manufacturer;\n                    ``(B) the establishment of procedures under which \n                discounted prices are provided to applicable \n                beneficiaries at pharmacies or by mail order service at \n                the point-of-sale of an applicable drug;\n                    ``(C) the establishment of procedures to ensure \n                that, not later than the applicable number of calendar \n                days after the dispensing of an applicable drug by a \n                pharmacy or mail order service, the pharmacy or mail \n                order service is reimbursed for an amount equal to the \n                difference between--\n                            ``(i) the negotiated price of the \n                        applicable drug; and\n                            ``(ii) the discounted price of the \n                        applicable drug;\n                    ``(D) the establishment of procedures to ensure \n                that the discounted price for an applicable drug under \n                this section is applied before any coverage or \n                financial assistance under other health benefit plans \n                or programs that provide coverage or financial \n                assistance for the purchase or provision of \n                prescription drug coverage on behalf of applicable \n                beneficiaries as the Secretary may specify; and\n                    ``(E) providing a reasonable dispute resolution \n                mechanism to resolve disagreements between \n                manufacturers, applicable beneficiaries, and the third \n                party with a contract under subsection (d)(3).\n            ``(2) Monitoring compliance.--\n                    ``(A) In general.--The Secretary shall monitor \n                compliance by a manufacturer with the terms of an \n                agreement under this section.\n                    ``(B) Notification.--If a third party with a \n                contract under subsection (d)(3) determines that the \n                manufacturer is not in compliance with such agreement, \n                the third party shall notify the Secretary of such \n                noncompliance for appropriate enforcement under \n                subsection (e).\n            ``(3) Collection of data from prescription drug plans and \n        ma-pd plans.--The Secretary may collect appropriate data from \n        prescription drug plans and MA-PD plans in a timeframe that \n        allows for discounted prices to be provided for applicable \n        drugs under this section.\n    ``(d) Administration.--\n            ``(1) In general.--Subject to paragraph (2), the Secretary \n        shall provide for the implementation of this section, including \n        the performance of the duties described in subsection (c).\n            ``(2) Limitation.--In providing for the implementation of \n        this section, the Secretary shall not receive or distribute any \n        funds of a manufacturer under the program.\n            ``(3) Contract with third parties.--The Secretary shall \n        enter into a contract with 1 or more third parties to \n        administer the requirements established by the Secretary in \n        order to carry out this section. At a minimum, the contract \n        with a third party under the preceding sentence shall require \n        that the third party--\n                    ``(A) receive and transmit information between the \n                Secretary, manufacturers, and other individuals or \n                entities the Secretary determines appropriate;\n                    ``(B) receive, distribute, or facilitate the \n                distribution of funds of manufacturers to appropriate \n                individuals or entities in order to meet the \n                obligations of manufacturers under agreements under \n                this section;\n                    ``(C) provide adequate and timely information to \n                manufacturers, consistent with the agreement with the \n                manufacturer under this section, as necessary for the \n                manufacturer to fulfill its obligations under this \n                section; and\n                    ``(D) permit manufacturers to conduct periodic \n                audits, directly or through contracts, of the data and \n                information used by the third party to determine \n                discounts for applicable drugs of the manufacturer \n                under the program.\n            ``(4) Performance requirements.--The Secretary shall \n        establish performance requirements for a third party with a \n        contract under paragraph (3) and safeguards to protect the \n        independence and integrity of the activities carried out by the \n        third party under the program under this section.\n            ``(5) Implementation.--The Secretary may implement the \n        program under this section by program instruction or otherwise.\n            ``(6) Administration.--Chapter 35 of title 44, United \n        States Code, shall not apply to the program under this section.\n    ``(e) Enforcement.--\n            ``(1) Audits.--Each manufacturer with an agreement in \n        effect under this section shall be subject to periodic audit by \n        the Secretary.\n            ``(2) Civil money penalty.--\n                    ``(A) In general.--The Secretary may impose a civil \n                money penalty on a manufacturer that fails to provide \n                applicable beneficiaries discounts for applicable drugs \n                of the manufacturer in accordance with such agreement \n                for each such failure in an amount the Secretary \n                determines is equal to the sum of--\n                            ``(i) the amount that the manufacturer \n                        would have paid with respect to such discounts \n                        under the agreement, which will then be used to \n                        pay the discounts which the manufacturer had \n                        failed to provide; and\n                            ``(ii) 25 percent of such amount.\n                    ``(B) Application.--The provisions of section 1128A \n                (other than subsections (a) and (b)) shall apply to a \n                civil money penalty under this paragraph in the same \n                manner as such provisions apply to a penalty or \n                proceeding under section 1128A(a).\n    ``(f) Clarification Regarding Availability of Other Covered Part D \nDrugs.--Nothing in this section shall prevent an applicable beneficiary \nfrom purchasing a covered part D drug that is not an applicable drug \n(including a generic drug or a drug that is not on the formulary of the \nprescription drug plan or MA-PD plan that the applicable beneficiary is \nenrolled in).\n    ``(g) Definitions.--In this section:\n            ``(1) Applicable beneficiary.--The term "),"applicable\nbeneficiary' means an individual who, on the date of dispensing\na covered part D drug--\n",(0,r.kt)("inlineCode",{parentName:"p"},"(A) is enrolled in a prescription drug plan or an \n                MA-PD plan;\n                    "),"(B) is not enrolled in a qualified retiree\nprescription drug plan; and\n",(0,r.kt)("inlineCode",{parentName:"p"},"(C) has incurred costs, as determined in \n                accordance with section 1860D-2(b)(4)(C), for covered \n                part D drugs in the year that exceed the annual \n                deductible with respect to such individual for such \n                year, as specified in section 1860D-2(b)(1), section \n                1860D-14(a)(1)(B), or section 1860D-14(a)(2)(B), as \n                applicable.\n            "),"(2) Applicable drug.--The term ",(0,r.kt)("inlineCode",{parentName:"p"},"applicable drug', with \n        respect to an applicable beneficiary--\n                    ``(A) means a covered part D drug--\n                            ``(i) approved under a new drug application \n                        under section 505(c) of the Federal Food, Drug, \n                        and Cosmetic Act or, in the case of a biologic \n                        product, licensed under section 351 of the \n                        Public Health Service Act; and\n                            ``(ii)(I) if the PDP sponsor of the \n                        prescription drug plan or the MA organization \n                        offering the MA-PD plan uses a formulary, which \n                        is on the formulary of the prescription drug \n                        plan or MA-PD plan that the applicable \n                        beneficiary is enrolled in;\n                            ``(II) if the PDP sponsor of the \n                        prescription drug plan or the MA organization \n                        offering the MA-PD plan does not use a \n                        formulary, for which benefits are available \n                        under the prescription drug plan or MA-PD plan \n                        that the applicable beneficiary is enrolled in; \n                        or\n                            ``(III) is provided through an exception or \n                        appeal; and\n                    ``(B) does not include a selected drug (as defined \n                in section 1192(c)) during a price applicability period \n                (as defined in section 1191(b)(2)) with respect to such \n                drug.\n            ``(3) Applicable number of calendar days.--The term \n        "),"applicable number of calendar days' means--\n",(0,r.kt)("inlineCode",{parentName:"p"},"(A) with respect to claims for reimbursement \n                submitted electronically, 14 days; and\n                    "),"(B) with respect to claims for reimbursement\nsubmitted otherwise, 30 days.\n",(0,r.kt)("inlineCode",{parentName:"p"},"(4) Discounted price.--\n                    "),"(A) In general.--The term ",(0,r.kt)("inlineCode",{parentName:"p"},"discounted price' \n                means, with respect to an applicable drug of a \n                manufacturer dispensed during a year to an applicable \n                beneficiary--\n                            ``(i) who has not incurred costs, as \n                        determined in accordance with section 1860D-\n                        2(b)(4)(C), for covered part D drugs in the \n                        year that are equal to or exceed the annual \n                        out-of-pocket threshold specified in section \n                        1860D-2(b)(4)(B)(i) for the year, 90 percent of \n                        the negotiated price of such drug; and\n                            ``(ii) who has incurred such costs, as so \n                        determined, in the year that are equal to or \n                        exceed such threshold for the year, 70 percent \n                        of the negotiated price of such drug.\n                    ``(B) Clarification.--Nothing in this section shall \n                be construed as affecting the responsibility of an \n                applicable beneficiary for payment of a dispensing fee \n                for an applicable drug.\n                    ``(C) Special case for certain claims.--\n                            ``(i) Claims spanning deductible.--In the \n                        case where the entire amount of the negotiated \n                        price of an individual claim for an applicable \n                        drug with respect to an applicable beneficiary \n                        does not fall above the annual deductible \n                        specified in section 1860D-2(b)(1) for the \n                        year, the manufacturer of the applicable drug \n                        shall provide the discounted price under this \n                        section on only the portion of the negotiated \n                        price of the applicable drug that falls above \n                        such annual deductible.\n                            ``(ii) Claims spanning out-of-pocket \n                        threshold.--In the case where the entire amount \n                        of the negotiated price of an individual claim \n                        for an applicable drug with respect to an \n                        applicable beneficiary does not fall entirely \n                        below or entirely above the annual out-of-\n                        pocket threshold specified in section 1860D-\n                        2(b)(4)(B)(i) for the year, the manufacturer of \n                        the applicable drug shall provide the \n                        discounted price--\n                                    ``(I) in accordance with \n                                subparagraph (A)(i) on the portion of \n                                the negotiated price of the applicable \n                                drug that falls below such threshold; \n                                and\n                                    ``(II) in accordance with \n                                subparagraph (A)(ii) on the portion of \n                                such price of such drug that falls at \n                                or above such threshold.\n            ``(5) Manufacturer.--The term "),"manufacturer' means any\nentity which is engaged in the production, preparation,\npropagation, compounding, conversion, or processing of\nprescription drug products, either directly or indirectly by\nextraction from substances of natural origin, or independently\nby means of chemical synthesis, or by a combination of\nextraction and chemical synthesis. Such term does not include a\nwholesale distributor of drugs or a retail pharmacy licensed\nunder State law.\n",(0,r.kt)("inlineCode",{parentName:"p"},"(6) Negotiated price.--The term `negotiated price' has \n        the meaning given such term in section 423.100 of title 42, \n        Code of Federal Regulations (or any successor regulation), \n        except that, with respect to an applicable drug, such \n        negotiated price shall not include any dispensing fee for the \n        applicable drug.\n            "),"(7) Qualified retiree prescription drug plan.--The term\n`qualified retiree prescription drug plan' has the meaning\ngiven such term in section 1860D-22(a)(2).''.\n(2) Sunset of medicare coverage gap discount program.--\nSection 1860D-14A of the Social Security Act (42 U.S.C. 1395-\n114a) is amended--\n(A) in subsection (a), in the first sentence, by\nstriking ",(0,r.kt)("inlineCode",{parentName:"p"},"The Secretary'' and inserting "),"Subject to\nsubsection (h), the Secretary''; and\n(B) by adding at the end the following new\nsubsection:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(h) Sunset of Program.--\n            "),"(1) In general.--The program shall not apply with respect\nto applicable drugs dispensed on or after January 1, 2024, and,\nsubject to paragraph (2), agreements under this section shall\nbe terminated as of such date.\n",(0,r.kt)("inlineCode",{parentName:"p"},"(2) Continued application for applicable drugs dispensed \n        prior to sunset.--The provisions of this section (including all \n        responsibilities and duties) shall continue to apply after \n        January 1, 2024, with respect to applicable drugs dispensed \n        prior to such date.''.\n            (3) Inclusion of actuarial value of manufacturer discounts \n        in bids.--Section 1860D-11 of the Social Security Act (42 \n        U.S.C. 1395w-111) is amended--\n                    (A) in subsection (b)(2)(C)(iii)--\n                            (i) by striking "),"assumptions regarding the\nreinsurance'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"assumptions \n                        regarding--\n                                    "),"(I) the reinsurance''; and\n(ii) by adding at the end the following:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(II) for 2024 and each subsequent \n                                year, the manufacturer discounts \n                                provided under section 1860D-14C \n                                subtracted from the actuarial value to \n                                produce such bid; and''; and\n                    (B) in subsection (c)(1)(C)--\n                            (i) by striking "),"an actuarial valuation of\nthe reinsurance'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"an actuarial \n                        valuation of--\n                            "),"(i) the reinsurance'';\n(ii) in clause (i), as inserted by clause\n(i) of this subparagraph, by adding ",(0,r.kt)("inlineCode",{parentName:"p"},"and'' at \n                        the end; and\n                            (iii) by adding at the end the following:\n                            "),"(ii) for 2024 and each subsequent year,\nthe manufacturer discounts provided under\nsection 1860D-14C;''.\n(d) Conforming Amendments.--\n(1) Section 1860D-2 of the Social Security Act (42 U.S.C.\n1395w-102) is amended--\n(A) in subsection (a)(2)(A)(i)(I), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},", \n                or an increase in the initial'' and inserting "),"or, for\na year preceding 2024, an increase in the initial'';\n(B) in subsection (c)(1)(C)--\n(i) in the subparagraph heading, by\nstriking ",(0,r.kt)("inlineCode",{parentName:"p"},"at initial coverage limit''; and\n                            (ii) by inserting "),"for a year preceding\n2024 or the annual out-of-pocket threshold\nspecified in subsection (b)(4)(B) for the year\nfor 2024 and each subsequent year'' after\n",(0,r.kt)("inlineCode",{parentName:"p"},"subsection (b)(3) for the year'' each place \n                        it appears; and\n                    (C) in subsection (d)(1)(A), by striking "),"or an\ninitial'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"or, for a year preceding \n                2024, an initial''.\n            (2) Section 1860D-4(a)(4)(B)(i) of the Social Security Act \n        (42 U.S.C. 1395w-104(a)(4)(B)(i)) is amended by striking "),"the\ninitial'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024, the \n        initial''.\n            (3) Section 1860D-14(a) of the Social Security Act (42 \n        U.S.C. 1395w-114(a)) is amended--\n                    (A) in paragraph (1)--\n                            (i) in subparagraph (C), by striking "),"The\ncontinuation'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the continuation'';\n                            (ii) in subparagraph (D)(iii), by striking \n                        "),"1860D-2(b)(4)(A)(i)(I)'' and inserting\n",(0,r.kt)("inlineCode",{parentName:"p"},"1860D-2(b)(4)(A)(i)(I)(aa)''; and\n                            (iii) in subparagraph (E), by striking \n                        "),"The elimination'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the elimination''; and\n                    (B) in paragraph (2)--\n                            (i) in subparagraph (C), by striking "),"The\ncontinuation'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the continuation''; and\n                            (ii) in subparagraph (E), by striking \n                        "),"1860D-2(b)(4)(A)(i)(I)'' and inserting\n",(0,r.kt)("inlineCode",{parentName:"p"},"1860D-2(b)(4)(A)(i)(I)(aa)''.\n            (4) Section 1860D-21(d)(7) of the Social Security Act (42 \n        U.S.C. 1395w-131(d)(7)) is amended by striking "),"section 1860D-\n2(b)(4)(B)(i)'' and inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"section 1860D-2(b)(4)(C)(i)''.\n            (5) Section 1860D-22(a)(2)(A) of the Social Security Act \n        (42 U.S.C. 1395w-132(a)(2)(A)) is amended--\n                    (A) by striking "),"the value of any discount'' and\ninserting the following: ",(0,r.kt)("inlineCode",{parentName:"p"},"the value of--\n                            "),"(i) for years prior to 2024, any\ndiscount'';\n(B) in clause (i), as inserted by subparagraph (A)\nof this paragraph, by striking the period at the end\nand inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"; and''; and\n                    (C) by adding at the end the following new clause:\n                            "),"(ii) for 2024 and each subsequent year,\nany discount provided pursuant to section\n1860D-14C.''.\n(6) Section 1860D-41(a)(6) of the Social Security Act (42\nU.S.C. 1395w-151(a)(6)) is amended--\n(A) by inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for a year before 2024'' after \n                "),"1860D-2(b)(3)''; and\n(B) by inserting ",(0,r.kt)("inlineCode",{parentName:"p"},"for such year'' before the \n                period.\n            (7) Section 1860D-43 of the Social Security Act (42 U.S.C. \n        1395w-153) is amended--\n                    (A) in subsection (a)--\n                            (i) by striking paragraph (1) and inserting \n                        the following:\n            "),"(1) participate in--\n",(0,r.kt)("inlineCode",{parentName:"p"},"(A) for 2011 through 2023, the Medicare coverage \n                gap discount program under section 1860D-14A; and\n                    "),"(B) for 2024 and each subsequent year, the\nmanufacturer discount program under section 1860D-\n14C;'';\n(ii) by striking paragraph (2) and\ninserting the following:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(2) have entered into and have in effect--\n                    "),"(A) for 2011 through 2023, an agreement described\nin subsection (b) of section 1860D-14A with the\nSecretary; and\n",(0,r.kt)("inlineCode",{parentName:"p"},"(B) for 2024 and each subsequent year, an \n                agreement described in subsection (b) of section 1860D-\n                14C with the Secretary; and''; and\n                            (iii) by striking paragraph (3) and \n                        inserting the following:\n            "),"(3) have entered into and have in effect, under terms and\nconditions specified by the Secretary--\n",(0,r.kt)("inlineCode",{parentName:"p"},"(A) for 2011 through 2023, a contract with a \n                third party that the Secretary has entered into a \n                contract with under subsection (d)(3) of section 1860D-\n                14A; and\n                    "),"(B) for 2024 and each subsequent year, a contract\nwith a third party that the Secretary has entered into\na contract with under subsection (d)(3) of section\n1860D-14C.''; and\n(B) by striking subsection (b) and inserting the\nfollowing:\n",(0,r.kt)("inlineCode",{parentName:"p"},"(b) Effective Date.--Paragraphs (1)(A), (2)(A), and (3)(A) of \nsubsection (a) shall apply to covered part D drugs dispensed under this \npart on or after January 1, 2011, and before January 1, 2024, and \nparagraphs (1)(B), (2)(B), and (3)(B) of such subsection shall apply to \ncovered part D drugs dispensed under this part on or after January 1, \n2024.''.\n            (8) Section 1927 of the Social Security Act (42 U.S.C. \n        1396r-8) is amended--\n                    (A) in subsection (c)(1)(C)(i)(VI), by inserting \n                before the period at the end the following: "),"or under\nthe manufacturer discount program under section 1860D-\n14C''; and\n(B) in subsection (k)(1)(B)(i)(V), by inserting\nbefore the period at the end the following: ``or under\nsection 1860D-14C''.\n(e) Effective Date.--The amendments made by this section shall\napply with respect to plan year 2024 and subsequent plan years."),(0,r.kt)("p",null,"SEC. 139202. ALLOWING CERTAIN ENROLLEES OF PRESCRIPTION DRUG PLANS AND\nMA-PD PLANS UNDER MEDICARE PROGRAM TO SPREAD OUT COST-\nSHARING UNDER CERTAIN CIRCUMSTANCES."),(0,r.kt)("pre",null,(0,r.kt)("code",{parentName:"pre"},"Section 1860D-2(b)(2) of the Social Security Act (42 U.S.C. 1395w-\n")),(0,r.kt)("p",null,"102(b)(2)), as amended by section 139201, is further amended--\n(1) in subparagraph (A), by striking ",(0,r.kt)("inlineCode",{parentName:"p"},"Subject to \n        subparagraphs (C) and (D)'' and inserting "),"Subject to\nsubparagraphs (C), (D), and (E)''; and\n(2) by adding at the end the following new subparagraph:\n``(E) Enrollee option regarding spreading cost-\nsharing.--The Secretary shall establish by regulation a\nprocess under which, with respect to plan year 2024 and\nsubsequent plan years, a prescription drug plan or an\nMA-PD plan shall, in the case of a part D eligible\nindividual enrolled with such plan for such plan year\nwho is not a subsidy eligible individual (as defined in\nsection 1860D-14(a)(3)) and with respect to whom the\nplan projects that the dispensing of the first fill of\na covered part D drug to such individual will result in\nthe individual incurring costs that are equal to or\nabove the annual out-of-pocket threshold specified in\nparagraph (4)(B) for such plan year, provide such\nindividual with the option to make the coinsurance\npayment required under subparagraph (A) (for the\nportion of such costs that are not above such annual\nout-of-pocket threshold) in the form of periodic\ninstallments over the remainder of such plan year.''."))}l.isMDXComponent=!0}}]);